Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | ALPL | P05186 | 1/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | ALPG | P10696 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL28221159 | 0.98 | HDAC1 (0.62) | HDAC1HDAC6THRBKMT2AHDAC3 | |
| SCHEMBL5361880 | 0.88 | HDAC1 (0.74) | HDAC1HDAC6THRBKMT2AHDAC3 | |
| Nicotinyl Methylamide SCHEMBL30664356 | 0.85 | HDAC1 (0.69) | HDAC1HDAC6THRBKMT2AHDAC3 | |
| Nicotinyl Methylamide SCHEMBL129458 | 0.85 | HDAC1 (0.69) | HDAC1HDAC6THRBKMT2AHDAC3 | |
| Nicotinyl Methylamide SCHEMBL28560459 | 0.85 | HDAC1 (0.69) | HDAC1HDAC6THRBKMT2AHDAC3 | |
| SCHEMBL18136525 | 0.84 | KMT2A (0.63) | HDAC1HDAC6THRBKMT2AHDAC3 | |
| Nicotinyl Methylamide SCHEMBL5528294 | 0.83 | HDAC1 (0.67) | HDAC1HDAC6THRBKMT2AHDAC3 | |
| Nicotinyl Methylamide SCHEMBL9275531 | 0.83 | HDAC1 (0.67) | HDAC1HDAC6THRBKMT2AHDAC3 | |
| Nicotinyl Methylamide SCHEMBL29082835 | 0.83 | HDAC1 (0.67) | HDAC1HDAC6THRBKMT2AHDAC3 | |
| Nicotinyl Methylamide SCHEMBL4730618 | 0.83 | HDAC1 (0.67) | HDAC1HDAC6THRBKMT2AHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646048-B1 | STABLE HELICAL IONIC POLYPEPTIDES | UNIV ILLINOIS (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| WO-2016162785-A1 | NOVEL PYRIDINIUM COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2016-10-13 | — | — | WO | disclosed |
| US-9243040-B2 | Stable helical ionic polypeptides | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-01-26 | — | — | US | disclosed |
| US-20100184811-A1 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | BRIDGE BIORESEARCH RIGHTS (JERSEY) LIMITED (GB) | 2010-07-22 | — | — | US | disclosed |
| US-20090118233-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | MURAI HITOSHI | 2009-05-07 | — | — | US | disclosed |
| US-20090118233-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | MURAI HITOSHI | 2009-05-07 | — | — | US | disclosed |
| EP-2045242-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | Shionogi&Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-7358249-B2 | Heterocyclic compounds having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2008-04-15 | — | — | US | disclosed |
| US-7358249-B2 | Heterocyclic compounds having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2008-04-15 | — | — | US | disclosed |
| US-4111944-A | SUBSTITUTED 1,2,4-TRIAZOLES | MERCK & CO., INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-3963731-A | TREATMENT OF GOUT AND HYPERURICEMIA | MERCK & CO., INC. (US) | 1976-06-15 | — | — | US | disclosed |
| US-3947577-A | 1,2,4-TRIAZOLES | MERCK & CO., INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118233-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | CYP3A7, CDK7, CYP2A7 | HDAC1 21/4885HDAC6 1384/4885THRB 955/4885 |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | HDAC1 1628/4885HDAC6 110/4885THRB 4112/4885 |
| US-20100184811-A1 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | ODC1, OTC, ACACB | HDAC1 144/4885HDAC6 1068/4885THRB 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.